logo
A Bronx Hospital Is Investing in Its Nurses

A Bronx Hospital Is Investing in Its Nurses

New York Times14-05-2025
Good morning. It's Wednesday. Today we'll look at what a safety net hospital in the Bronx plans to do with a $5 million grant. We'll also get details on a judge's decision to put an outside official in charge of the troubled Rikers Island jail complex.
St. Barnabas Hospital plans to spend $5 million on a program for its nurses.
'Just because we treat poor people doesn't mean we shouldn't have the best possible staff,' said Dr. David Perlstein, the president and chief executive of St. Barnabas, a 422-bed hospital in the Bronx.
The money is from $51 million in grants from the Mother Cabrini Health Foundation, which was formed several years ago after the sale of Fidelis Care, a managed care company that had been set up by the Roman Catholic Church.
The foundation wanted to address the severe nursing shortage that existed before the pandemic and that was compounded when emergency rooms were overflowing with coronavirus patients, particularly at so-called safety net hospitals like St. Barnabas that typically have large numbers of patients who are on Medicaid or are uninsured.
The foundation targeted its grants to hard-pressed hospitals that wanted to apply for nursing accreditation programs. It said that St. Barnabas and 12 other institutions, including Calvary Hospital and Montefiore Medical Center, both in the Bronx, would use grant money for programs overseen by the American Nurses Credentialing Center.
'There are no safety nets doing these programs because they're expensive programs,' Perlstein said. 'We can't compete' with larger hospitals that are affiliated with medical schools 'and have the funding to cover programs that should be offered everywhere,' he said.
The hospitals receiving grants will have to undergo a rigorous review by the credentialing center, an independent body, to be certified. 'We believe there's a lot of value in the pursuit of accreditation,' said Anupa Fabian, Mother Cabrini's chief research officer. That 'will help hospitals put structures in place that lead to significant improvements in nurse well-being' — and, ultimately, patient care.
Rebecca Graystone, a senior vice president of the credentialing center, said the grants from Mother Cabrini were the most by a private foundation for safety net organizations in the United States. 'The $51 million, we believe, has the ability to absolutely transform care delivery,' she said. 'If you don't have nurses in a hospital whose well-being is taken care of, whose work environment is appropriate, hospitals don't run. Whatever brings the patient to the front door of an institution, it's the nursing staff that gets them admitted.'
Msgr. Gregory Mustaciuolo, the chief executive of the foundation, put it more simply: 'You can't have health care without nurses.' Still, he called the grants 'a drop in the bucket,' adding that they 'will not in any way solve the problem.'
Other foundation officials said that stress and burnout had contributed to the nursing shortage. They cited a statewide study by the Center for Health Workforce Studies at the University of Albany, which found that just under half of nurses surveyed reported symptoms of burnout in 2023. The center also found that retirements were not the only factor in staff shortages. Younger nurses were moving on as well: About 15 percent of hospital nurses between 20 and 39 planned to leave their current jobs within 12 months.
Perlstein said the accreditation program at St. Barnabas would involve 'shared governance and engagement' with nurses. The program will also provide more possibilities for career development for nurses 'who want to be something more or something else,' he said.
Nadine Williamson, a senior vice president of 1199 SEIU, the union that represents nurses at St. Barnabas, called the grant 'amazing' and 'historic.' Noting that nurses there are among the lowest paid in the city, she added that the accreditation program should help with recruiting and retaining nurses.
'If the nurses feel good, they're going to give quality health care,' she said, 'and the morale of the nurses lifts up the entire team.'
Expect a rainy day with the possibility of thunderstorms. The temperature will hover in the low to mid-60s, day and evening, as the downpours continue.
In effect until May 26 (Memorial Day).
The latest Metro news
An outside official will take charge of Rikers, a judge orders
A federal judge seized control on Tuesday of the Rikers Island jails, which have been rife with violence and dysfunction.
The judge, Laura Taylor Swain, ordered the appointment of an outside official 'empowered to take all actions necessary' to turn Rikers around. Shunning Mayor Eric Adams's efforts to retain control of the lockups, she said the new remediation manager would not be a city employee and would report directly to her.
The city had managed to hold onto control of Rikers, struggling to show progress, as critics of the system called for a receiver to be put in charge. Conditions have not improved, according to lawyers in a class-action lawsuit and the federal monitor who has issued reports on conditions at Rikers regularly for nearly a decade. In November, the judge found the city in contempt for failing to stem violence and excessive force at the jail.
Judge Swain's ruling was another blow for Adams, who is running for re-election as an independent after dropping out of the crowded Democratic field. He was indicted on federal corruption charges last year. But a judge dismissed the charges last month after the Justice Department said that going ahead with the case would keep the mayor from making good on his promise to cooperate with President Trump's crackdown on immigration.
The Legal Aid Society and a private law firm representing people incarcerated at Rikers had asked Judge Swain to take away the city's control of Rikers and to install a receiver who would answer only to her. They said the receiver should have broad authority that would extend to staffing and the union contracts that drive it.
The remediation manager will have 'broad powers' similar to those that the receiver sought by the plaintiffs would have had, the judge said.
The city wanted the Correction Department commissioner, Lynelle Maginley-Liddie, to take on another title as 'compliance director' and to answer to the court on issues like safety and staffing shortages while answering to Adams on everything else.
A New York Times investigation in 2021 found that guards were often stationed in inefficient ways that failed to protect detainees. In addition, an unlimited sick leave policy meant that the staff was often short-handed.
Adams said on Tuesday that the 'problems at Rikers are decades in the making.' He blamed a law requiring Rikers to be shut down by 2027 for preventing upgrades to the complex. The city is not expected to meet that deadline.
Sunshine Boy
Dear Diary:
It was spring 1975. I was 23 and had been in New York for less than six months. I was working as a secretary at Artkraft Strauss, and 'The Sunshine Boys' was filming around the corner.
During one lunch hour, Walter Matthau appeared in a shabby overcoat. Gathering all of my courage, I asked him for an autograph.
Almost smiling, he asked my name.
I panicked. Should I ask for two autographs? Would that be too much? I decided not to risk it.
'Oh, it's not for me,' I said. 'It's for my mother, Ruth.'
Giving his best scowl, he scribbled a line and stomped off.
My mother still had that autograph when she died 13 years ago. I have it now.
— Amanda Sherwin
Illustrated by Agnes Lee. Send submissions here and read more Metropolitan Diary here.
Glad we could get together here. See you tomorrow. — J.B.
P.S. Here's today's Mini Crossword and Spelling Bee. You can find all our puzzles here.
Stefano Montali and Ed Shanahan contributed to New York Today. You can reach the team at nytoday@nytimes.com.
Sign up here to get this newsletter in your inbox.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test

Yahoo

time28 minutes ago

  • Yahoo

Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test

Company Launches New Website, Scales Test Access Alongside Mayo Clinic, & Looks to Expand International Presence SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic's network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer's Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616. Following its recent collaboration with Mayo Clinic Laboratories, Amprion launched a newly redesigned website to meet the growing demand for its SAAmplify-ɑSYN test, which aids in the diagnosis of synucleinopathies. The breakthrough test can detect the presence of aggregates of alpha-synuclein protein, the underlying pathology of Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer's disease with Lewy bodies (AD + DLB), in cerebrospinal fluid. Launched earlier this month, the updated website is designed to provide patients, clinicians, and industry leaders with streamlined access to Amprion's latest research, information, and more. "As awareness and demand for our SAAmplify-ɑSYN test grow, we're working to ensure clinicians, researchers, and patients have better access to the tools and information they need," said Dr. Russ Lebovitz, CEO and co-founder of Amprion. "Our refreshed website and expanding partnerships are steps toward that goal, and we look forward to connecting with the global neuroscience community at AAIC." Due to this surge in awareness, Amprion is actively exploring international expansion opportunities, with plans to bring its test to European and global markets. Initial announcements regarding country-specific launch strategies are expected in Q4 2025. For more information or to schedule a meeting with Amprion at AAIC 2025, please visit About SAAmplify-ɑSYN (formerly SYNTap®) Amprion's SAAmplify-ɑSYN test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. The test became commercially available in the US in 2021. About Amprion Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at or find us on LinkedIn. View source version on Contacts Media Contacts Liz RobinsonCG Lifelrobinson@ Karen SharmaCG Lifeksharma@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Longest Shortest Time
The Longest Shortest Time

Yahoo

time28 minutes ago

  • Yahoo

The Longest Shortest Time

Credit - After a five-year hiatus, the parenting podcast hosted by This American Life contributor and author Hillary Frank returned with the help of Realm in 2025. The archives, spanning 2010 to 2019, delve into essential topics like whether to get genetic testing before having a baby and interview listeners for some fantastic tales like the twisty series on 'The Accidental Gay Parents.' But a lot has changed in Frank's life and the world of parenting since the show took a break. Frank started the podcast because of her disappointment with her own birth experience, which ended in a three-year-long painful recovery (as outlined in the moving episode 'Rewriting Your Birth Story'). Now her daughter is a teen, and in her first episode back, Frank interviews her child about what she's learning in sex ed. (Spoiler alert: the curriculum is frustratingly focused on anatomy rather than on consent.) Frank says she wants to shine a light on reproductive health in the show's new iteration and tell stories that have to do with attacks on bodily autonomy, how technology is changing how babies are made, how we talk to kids about sex, and new research on periods and menopause. In early episodes, New York Times writer Amanda Hess expounds on her complicated relationship with period and pregnancy apps; YouTuber and avid pilot Xyla Foxlin talks about her battle with the FAA over her birth control; and Sara Reardon, known online as the Vagina Whisperer, answers listener questions about the pelvic floor. All the new episodes elucidate supposedly taboo topics, from receiving bad news on an ultrasound to how our mental health is impacted by hormonal birth control to healing after childbirth, with personal and thoughtful stories. Write to Eliana Dockterman at Solve the daily Crossword

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Yahoo

time28 minutes ago

  • Yahoo

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

DURHAM, N.C., July 23, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). "Receipt of Orphan Drug Designation from the FDA for PBGENE-DMD underscores the tremendous unmet need and urgency to deliver safe treatments that significantly improve muscle function over time for boys living with Duchenne muscular dystrophy," said Cindy Atwell, Chief Development and Business Officer at Precision BioSciences. "This regulatory milestone builds on our recent receipt of Rare Pediatric Disease designation and, together with our preclinical body of evidence, gives us tremendous confidence as we move this program towards the clinic. Looking ahead, we remain in active dialogue with the FDA as we advance PBGENE-DMD toward regulatory milestones, with clinical data anticipated in 2026." The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides sponsors certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for that use. About PBGENE-DMD PBGENE-DMD is Precision's development program for the treatment of DMD. The approach uses two complementary ARCUS nucleases delivered via a one-time administration in a single AAV to excise exons 45-55 of the dystrophin gene with the aim of restoring near full-length dystrophin protein within the body to improve functional outcomes. PBGENE-DMD is intended to address up to 60% of the DMD patient population. In preclinical studies, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and produced significant, durable functional improvements in a humanized DMD mouse model. PBGENE-DMD restored the body's ability to produce a near full-length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement. PBGENE-DMD was recently granted FDA Rare Pediatric Disease (RPD) designation for the treatment of DMD. The Company is advancing the final IND-enabling toxicology studies and is working closely with leading DMD clinicians to design a first in human trial optimized for safety and efficacy. Clinical grade material is in preparation, with initial clinical data expected in 2026. About Precision BioSciences, Inc. Precision's two lead programs, PBGENE-HBV, for chronic Hepatitis B, and PBGENE-DMD, for Duchenne muscular dystrophy, are focused on areas with large patient populations with high unmet need. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline prioritizes in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our and our partners' and licensees' product candidates and gene editing approaches; the potential of PBGENE-DMD to safely drive meaningful improvement in functional and durable benefit over time for up to 60% of patients with DMD; the design on PBGENE-DMD to permanently edit a patient's own DNA sequence, resulting in naturally-produced, near full-length dystrophin protein proven known to be functional in humans; the benefits of an Orphan Drug Designation including financial incentives and regulatory exclusivity; the potential value of a Priority Review Voucher(if awarded) including priority review for a different product or sale to another sponsor; the expected timing of regulatory processes and clinical operations (including IND and/or CTA filings, studies, enrollment and clinical data for PBGENE-DMD; and anticipated timing of clinical data. In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "appear," "approach," "believe," , "confidence", "contemplate," "could," "design" "designed," "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should," "strive," "suggest," "target," "will," "would," or the negative thereof and similar words and expressions. Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim "top-line" and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at and the Investors page of our website under SEC Filings at All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. View source version on Contacts Investor and Media Contact: Naresh TannaVice President of Investor

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store